Time and Location
All seminars are Noon-1:15 pm in
E9519 unless otherwise noted. Lunch
will be provided.
October 19, 2015
Kay Dickersin, PhD
Director, Center for Clinical Trials and
Evidence Synthesis
Bloomberg School of Public Health
November 30, 2015
Gerald Dal Pan, MD, MHS
Director, Office of Surveillance and
Epidemiology, CDER
Food and Drug Administration
December 14, 2015
Nancy Santanello, MD, MS, FISPE
Former Vice-President of
Epidemiology, Merck
January 25, 2016
Bimal Shah, MD
Vice President
Premier Research Services
Premier, Inc.
*Room W2008
February 29, 2016
William Shrank, MD, MSHS
Senior Vice President,
Chief Scientific and Medical Officer,
CVS Health
April 6, 2016
Rita Redberg, MD, FACC, MSc
Editor
JAMA Internal Medicine;
Professor of Medicine
University of California, San Francisco
April 18, 2016
Dan Budnitz, MD, MPH
Director, Medication Safety Program
Centers for Disease Control and
Prevention
May 9, 2016
Jon Resnick
Vice President and General Manager
Real-World Evidence Solutions
IMS Health
About the Seminar Series
Pharmaceuticals exist in a dynamic
landscape. Scientific discovery is continuous, while patients, clinicians, researchers and policy-makers face the
challenge of synthesizing new evidence
and using it to optimally inform clinical
decision-making. Many features of the
contemporary marketplace make these
opportunities particularly important, including healthcare reform and redesign,
changes in the composition of the drug
marketplace, growth of health information technologies and increasing efforts
by payers to leverage comparative
effectiveness and extract greater value
from pharmaceuticals. This seminar brings
together nationally renowned leaders
reflecting key stakeholders – government,
academia, and the life sciences industry –
in order to focus on three key themes of
pharmaceutical development and delivery
in the current decade: safety, value and
innovation
About the Center
Pharmaceuticals play a vital role in the health and longevity of millions, yet many challenges prevent their optimal use. The
goal of the Center for Drug Safety and Effectiveness is to improve the safe and effective use of medications. Drawing on the
combined expertise of the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins Medicine, the Center serves
as a nexus for individuals at Johns Hopkins who are involved in research, education, clinical programs and public service to
improve prescription drug use and pharmaceutical policy in the US and around the world. In addition to its work with trainees
and junior faculty and involvement with Johns Hopkins Medicine initiatives, the Center maintains partnerships with a variety
of other stakeholders vested in addressing core problem areas ranging from prescription drug abuse to barriers to accessible
medicines in developing countries.